RxDoctor Payments Data

Tyra Carter

Family · Ellicott City, MDNPI 1124012711

Payments from drug & device makers

$1,581in general payments, 2019–2025

Across 23 payments — averaging $68.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$294
  • Alpha Cognition USA, Inc.$250
  • Idorsia Pharmaceuticals US Inc$211
  • Boston Scientific$138
  • Teva Pharmaceuticals USA, Inc.$122
  • AbbVie$121
  • plus $445 from 5 others

What the payments were for

  • Food & beverage$1,581100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,581 in reported general payments places this provider in the 75th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$363,397
Medicare patients
239
Services billed
3,916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala40$160,695
EliquisApixaban213$132,759
GemtesaVibegron130$65,923
OzempicSemaglutide54$54,101
JardianceEmpagliflozin55$33,962
Breo ElliptaFluticasone/Vilanterol55$23,648
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$19,753
XareltoRivaroxaban37$18,842
TrulicityDulaglutide17$17,489
EntrestoSacubitril/Valsartan24$17,099
MounjaroTirzepatide15$16,582
Atorvastatin Calcium1,006$13,165
LokelmaSodium Zirconium Cyclosilicate12$10,535
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$7,381
LinzessLinaclotide12$6,940

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$294$65,923130 claims
Johnson & JohnsonXarelto$19$18,84237 claims
AbbVieLinzess$121$6,94012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,843 family providers in Maryland.

Other family in Ellicott City

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →